Catalyst Intel Subscribe

Trial results

$PBLS — zolucatetide

Parabilis Medicines, Inc. (PBLS) zolucatetide: trial results in desmoid tumors, 2027.

Research by Catalyst Intel

The catalyst

"We plan to initiate a global registrational Phase 3 trial for zolucatetide in patients with desmoid tumors in the first half of 2027 with topline results anticipated in 2029."

— FogPharma, Inc., 10-Q filed 2026-11-12 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id
PBLS-ZOLUCATETIDE-2026
Company
Parabilis Medicines, Inc.
Kind
Trial results
Indication
desmoid tumors
Window
2027-01-01 – 2027-06-30
Status
dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.